<DOC>
	<DOCNO>NCT01431222</DOCNO>
	<brief_summary>The primary objective randomize trial evaluate safety efficacy MitraClip treatment symptomatic patient severe mitral regurgitation comparison previous default medical treatment - study population amenable conventional surgical approach current gold standard .</brief_summary>
	<brief_title>Abrogation Mitral Regurgitation Using MitraClip System High-Risk Patients Unsuitable Surgery</brief_title>
	<detailed_description>The presence significant mitral regurgitation ( MR ) seriously effect patient ` quality life associate increased mortality rate . The operative treatment MR - either mitral valve repair replacement - current gold standard . However mere half patient severe symptomatic MR actually undergo operative treatment ( EURO-HEART-SURVEY ) due restrict leave ventricular ejection fraction , elderly patient co-morbidities high perioperative morbidity mortality . In contrast , patient severe symptomatic MR suitable operation treat palliative medical therapy ( heart insufficiency therapy ) . With development MitraClip device - minimal-invasive , percutaneous catheter-based technique - high-risk patient suitable surgery may receive promise alternative treatment approximate mitral leaflet , thus create permanent leaflet coaptation reduce even abrogate MR . The current data support assumption safe effective MR reduction MitraClip-System inoperable high-risk patient severe MR . But feasibility still prove special patient population .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>age ≥ 18 year sign write consent symptomatic patient ( NYHAstadium ≥ III ) least 3 month exploit medical heart insufficiency therapy increase perioperative risk logistic EuroScore ≥ 15 STSScore ≥ 15 MR grade ≥ 2 , amenable MitraClip intervention assess experienced interventional cardiologist Affirmation inoperability `` HeartTeam '' consist either 1 cardiac surgeon 1 cardiologist 3 cardiologist one essential cardiovascular event past 6 week ; i. e. myocardial infarction , stroke , shock , cardiac decompensation , necessity catecholamine therapy haemodynamic stabilisation implantation biventricular pacemakerdevice cardiac resynchronisation therapy past 3 month solid tumor live expectancy &lt; 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>severe mitral regurgitation</keyword>
	<keyword>interventional mitral valve reconstruction</keyword>
	<keyword>inoperable</keyword>
	<keyword>EuroSCORE</keyword>
	<keyword>STS Risk Score</keyword>
	<keyword>MitraClip</keyword>
	<keyword>fluoroscopy</keyword>
	<keyword>echocardiography</keyword>
	<keyword>percutaneous treatment mitral regurgitation</keyword>
</DOC>